The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Clinical Cancer Research|2015Cited by 18
CD4+ T Cells in High-Risk MDS Patients Bear an Aberrant STAT Signaling BiosignatureEleftheria Lamprianidou, Ιoannis Kotsianidis, Evangelia Nakou et al.|Blood|2014Cited by 1
Data from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Unknown|2023Cited by 0
Supplementary Table S2 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Unknown|2023Cited by 0
Supplementary Figure S5 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Unknown|2023Cited by 0